Liposomal ciprofloxacin: Phase IIb data

Top-line data from the double-blind, Australian and New Zealand Phase IIb ORBIT-2 trial in 42 patients showed that once-daily inhaled ARD-3150 met the primary endpoint of significantly reducing mean P. aeruginosa density in sputum from baseline to day 28 vs. placebo (4.2 log10 vs. 0.1 log10 colony forming units (CFUs)/gram, p=0.004). ARD-3150 also met the secondary endpoint of significantly reducing the number of patients requiring supplemental antibiotics for respiratory-related infections vs. placebo (8 vs. 17, p=0.05). ...